ProKidney Corp
PROK1.870USD
+0.140+8.09%
終値 02/06, 16:00（ET）15分遅れの株価
254.28M時価総額
損失額直近12ヶ月PER
詳細情報 ProKidney Corp 企業名
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
ProKidney Corpの企業情報
企業コードPROK
会社名Prokidney Corp
上場日Jun 30, 2021
最高経営責任者「CEO」Culleton (Bruce)
従業員数204
証券種類Ordinary Share
決算期末Jun 30
本社所在地2000 Frontis Plaza Blvd
都市WINSTON-SALEM
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号27103
電話番号13369997028
ウェブサイトhttps://prokidney.com/
企業コードPROK
上場日Jun 30, 2021
最高経営責任者「CEO」Culleton (Bruce)
ProKidney Corpの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
+1537020.00%
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Alan M. Lotvin, M.D.
Dr. Alan M. Lotvin, M.D.
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Mr. Jose Ignacio Jimenez Santos
Mr. Jose Ignacio Jimenez Santos
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
+1537020.00%
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sun, Nov 16
更新時刻: Sun, Nov 16
株主統計
種類
株主統計
株主統計
比率
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
他の
60.77%
株主統計
株主統計
比率
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
他の
60.77%
種類
株主統計
比率
Corporation
23.56%
Hedge Fund
11.04%
Investment Advisor
10.26%
Investment Advisor/Hedge Fund
6.12%
Individual Investor
1.83%
Research Firm
0.90%
Endowment Fund
0.71%
Bank and Trust
0.04%
Family Office
0.02%
他の
45.52%
機関投資家保有株
更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
178
41.07M
29.01%
-2.81M
2025Q3
180
38.60M
28.59%
-15.99M
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
2023Q3
236
64.28M
104.12%
-21.16M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Tolerantia LLC
22.62M
15.98%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
8.72%
--
--
Sep 30, 2025
Control Empresarial de Capitales, S.A. de C.V.
10.72M
7.58%
+2.28M
+27.04%
Apr 22, 2025
Morgan Stanley Investment Management Inc. (US)
6.41M
4.53%
+698.99K
+12.24%
Sep 30, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.42%
--
--
Oct 31, 2025
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.73%
--
--
Nov 30, 2025
Bleichroeder LP
2.00M
1.41%
--
--
Sep 30, 2025
Millennium Management LLC
1.96M
1.38%
+1.96M
--
Sep 30, 2025
The Vanguard Group, Inc.
1.56M
1.1%
-3.75K
-0.24%
Sep 30, 2025
Culleton (Bruce)
1.54M
1.09%
+1.54M
--
Mar 17, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Schwab U.S. Small-Cap ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
詳細を見る
Schwab U.S. Small-Cap ETF
比率0.01%
ALPS Medical Breakthroughs ETF
比率0%
Global X Russell 2000 Covered Call ETF
比率0%
Schwab U.S. Broad Market ETF
比率0%
ProShares UltraPro Russell2000
比率0%
ProShares Hedge Replication ETF
比率0%
iShares Russell 2000 ETF
比率0%
Avantis US Equity ETF
比率0%
Global X Russell 2000 ETF
比率0%
iShares Russell 2000 Growth ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
